Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids
Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids
This study is designed to prospectively investigate the feasibility of establishing
 patient-derived tumoroids (PDT) as a platform for a personalized approach for response
 prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated
 to determine drug sensitivity, predict the response to chemotherapy agents and radiation
 therapy, and validate this response in treated patients, and to establish the feasibility of
 PDT as a platform for a personalized approach to guide multimodality treatment.
Inclusion Criteria:

 -  Age ≥ 18 years of age.

 -  Have an ECOG Performance Status of ≤ 2.

 -  No evidence of distant metastasis on imaging.

 -  Histologic or cytologic proven adenocarcinoma of the pancreas.

 -  Providing informed consent prior to enrollment in the trial.

 Exclusion Criteria:

 -  Failure to obtain additional core needle biopsies for generating PDTs.

 -  Females who are pregnant or plan to become pregnant.